Evidence map›Paper›PMID 40529043›Full record

ArticleTranslational andrology and urology2025

Mirabegron efficacy as medical expulsive therapy for distal ureteral stones: a systematic review of the literature, meta-analysis and trial sequential analysis.

Richard Dobrucki de Lima, Lucas Schenk de Almeida, Breno Cordeiro Porto, Nathalie Cordeiro Hobaica, Carlo Camargo Passerotti, Rodrigo A S Sardenberg, José Pinhata Otoch, José Arnaldo Shiomi da Cruz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Richard Dobrucki de LimaDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Lucas Schenk de AlmeidaDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Breno Cordeiro PortoDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Nathalie Cordeiro HobaicaDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Carlo Camargo PasserottiDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Rodrigo A S SardenbergInternational Teaching and Research Institute, Hapvida NotreDame Intermédica, São Paulo, SP, Brazil.
José Pinhata OtochDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
José Arnaldo Shiomi da CruzDepartment of Surgical Technique and Experimental Surgery, University of São Paulo School of Medicine, São Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medical expulsive therapy (MET) is recommended for distal ureteral stones measuring 5 to 10 mm. Mirabegron, a β3-adrenergic agonist, has been proposed as a potential agent to improve stone expulsion rate (SER) and stone expulsion time (SET). This study aims to evaluate the efficacy of mirabegron compared to placebo for MET in distal ureteral stones. Methods: A systematic literature search was conducted in PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception until December 2023. Only randomized controlled trials (RCTs) were included in the analysis. Results: Five RCTs including 419 patients were analyzed. No significant differences were observed between mirabegron and placebo for SER [risk ratio (RR): 1.49, 95% confidence interval (CI): 0.91-2.45, P=0.08, I Conclusions: Mirabegron does not provide a significant benefit as a MET for distal ureteral stones measuring 5 to 10 mm. Further RCTs are necessary to establish its potential role in ureterolithiasis management.

Indexed as

expulsive therapymirabegronureteral calculiUreteral stonesurolithiasis

Identifiers

PMID40529043
PMCPMC12170219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.